The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | Incorporating immunotherapy in the treatment landscape of SCLC
Bjørn Henning Grønberg, MD, PhD, Norwegian University of Science and Technology, Trondheim, Norway, comments potential combination therapies involving radiotherapy for small-cell lung cancer (SCLC). Whilst the Phase III ADRIATIC trial (NCT03703297) demonstrated the benefits of adding immunotherapy to existing chemoradiotherapy, Prof. Grønberg highlights the importance of chemoradiotherapy in the management of SCLC. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
